Clinical Trials
31 trialsImatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI
Asan Medical Center
KISS
University of Auckland, New Zealand
Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma
Keio University
EMMBKM
Xijing Hospital
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy
Samsung Medical Center
SUSTRENIM
Gruppo Italiano Malattie EMatologiche dell'Adulto
EWALL-Ph-03
Cardiff University
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment
Shanghai Zhongshan Hospital
HU
First Affiliated Hospital of Harbin Medical University
Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation
Shanghai Zhongshan Hospital
Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia
Nanfang Hospital, Southern Medical University
Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia
Assiut University
The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia
The University of Hong Kong
Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
National University Hospital, Singapore
GITIC
Sun Yat-sen University
SESPI
Tongji Hospital
GIGIST
Assistance Publique Hopitaux De Marseille
RE-NICE
Seoul St. Mary's Hospital
Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)
Hospital Santa Marcelina
A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma
Peking University Cancer Hospital & Institute
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
University of Virginia
Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia
University of Glasgow
A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
Gruppo Italiano MEsotelioma
Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)
Johann Wolfgang Goethe University Hospital
Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck
Gustave Roussy, Cancer Campus, Grand Paris
AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year
Hospices Civils de Lyon
Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.
Hospices Civils de Lyon
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase
Central European Leukemia Study Group
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
Maisonneuve-Rosemont Hospital